Pemphigus Vulgaris Market Is Expected to Showcase a Significant Growth by 2032, Estimates DelveInsight | Key Companies – Principia Biopharma, Topas Therapeutics, and Argenx BVBA

Delveinsight Business Research LLP
DelveInsight’s “Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Pemphigus Vulgaris Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Pemphigus Vulgaris market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Pemphigus Vulgaris: An Overview

Pemphigus Vulgaris (PV) is a rare, severe autoimmune and intraepithelial disease characterized by flaccid blisters and erosions of the skin and mucous membrane. It is histologically marked by acantholysis and is mediated by circulating desmoglein-reactive autoantibodies, directed against keratinocyte cell surfaces.

 Pemphigus Vulgaris Market Key Facts

As per DelveInsight, the total diagnosed prevalent cases of Pemphigus Vulgaris in the 7MM were observed to be 42,400+ in 2020.

The estimates show the highest diagnosed prevalence of Pemphigus Vulgaris in the United States with 14,000+ cases in 2020.

Among the EU5 countries, Germany had the highest diagnosed prevalent population of Pemphigus Vulgaris with 7,600+ cases, followed by the United Kingdom with 6,900+ cases. On the other hand, France had the lowest diagnosed prevalent population of 2,600+ in 2020.

A female predominance in Pemphigus Vulgaris is well established. However, the genetic and physiological basis for this gender bias is not well understood.

PV is five times as prevalent as Pemphigus Foliaceous in the US. Desmoglein (Dsg) 3 is the major antigen in PV but 50–60% of patients have additional antibodies to Dsg1. The underlying antibody profile is the major determinant of the clinical phenotype.

Get the Sample PDF of the Report:- https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market

Key Benefits of Pemphigus Vulgaris Market Report

The report provides an in-depth analysis of Pemphigus Vulgaris Market Size and Share till 2032 in the 7MM.

The report will help in developing business strategies by understanding the Pemphigus Vulgaris Market Trends, key players, and ongoing developments activities, that shape and drive the market growth in the upcoming years.

It covers Pemphigus Vulgaris’ current treatment practices, emerging drugs, market share of the individual therapies in the 7MM.

The report provides a detailed assessment of the Pemphigus Vulgaris market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors. 

Pemphigus Vulgaris Market

As per DelveInsight, the Pemphigus Vulgaris market is expected to grow by factors like an increase in the prevalent pool, rising awareness among patients, the recent approval of MabThera/Rituxan, and the expected entry of emerging therapies.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Pemphigus Vulgaris market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives a thorough detail of the Pemphigus Vulgaris market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Pemphigus Vulgaris Epidemiology Forecast 

The epidemiology section covers insights about the historical and current Pemphigus Vulgaris patient pool and forecasted trends for every seven major countries (7MM)  from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Pemphigus Vulgaris (PV) Epidemiology Segmentation

Total Diagnosed Prevalent Cases of PV

Age-specific Diagnosed Prevalent Cases

Gender-specific Diagnosed Prevalent Cases of PV

Severity-specific Diagnosed Prevalent Cases of PV

Pemphigus Vulgaris Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pemphigus Vulgaris market or expected to get launched in the market during the study period. The analysis covers Pemphigus Vulgaris market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Pemphigus Vulgaris Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Pemphigus Vulgaris Therapeutics Analysis

Some of the key companies in the Pemphigus Vulgaris (PV) Market include:

Principia Biopharma

Topas Therapeutics

Argenx BVBA

And many others

Pemphigus Vulgaris (PV) Therapies covered in the report include:

TPM203

ARGX-113/Efgartigimod

Rilzabrutinib/PRN 1008

And many more

The approval of emerging products is expected to significantly impact the Pemphigus Vulgaris (PV) market during the forecast period.

Get the sample copy of the report, at: https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market

Table of Content

1. Key Insights

2. Executive Summary 

3. Pemphigus Vulgaris Competitive Intelligence Analysis

4. Pemphigus Vulgaris Market Overview at a Glance

5. Pemphigus Vulgaris Disease Background and Overview

6. Pemphigus Vulgaris Patient Journey

7. Pemphigus Vulgaris Epidemiology and Patient Population

8. Pemphigus Vulgaris Treatment Algorithm, Current Treatment, and Medical Practices

9. Pemphigus Vulgaris Unmet Needs

10. Key Endpoints of Pemphigus Vulgaris Treatment

11. Pemphigus Vulgaris Marketed Products

12. Pemphigus Vulgaris Emerging Therapies

13. Pemphigus Vulgaris Seven Major Market Analysis

14. Attribute Analysis

15. Pemphigus Vulgaris Market Outlook (7 major markets)

16. Pemphigus Vulgaris Access and Reimbursement Overview

17. KOL Views on the Pemphigus Vulgaris Market.

18. Pemphigus Vulgaris Market Drivers

19. Pemphigus Vulgaris Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Request Sample Report here:- https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/